Voyager Therapeutics, Inc. $VYGR Shares Acquired by American Century Companies Inc.

American Century Companies Inc. raised its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 7.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,521 shares of the company’s stock after acquiring an additional 8,795 shares during the period. American Century Companies Inc. owned 0.24% of Voyager Therapeutics worth $445,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VYGR. Cubist Systematic Strategies LLC acquired a new position in Voyager Therapeutics during the 4th quarter valued at approximately $29,000. Tower Research Capital LLC TRC boosted its position in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after purchasing an additional 3,077 shares during the period. CWM LLC boosted its position in Voyager Therapeutics by 856.3% during the 1st quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after purchasing an additional 9,376 shares during the period. Privium Fund Management B.V. acquired a new position in shares of Voyager Therapeutics during the first quarter valued at $73,000. Finally, Tema Etfs LLC acquired a new position in shares of Voyager Therapeutics during the fourth quarter valued at $85,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wedbush reduced their target price on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $13.25.

Voyager Therapeutics Stock Up 9.3%

VYGR stock opened at $4.24 on Friday. The company has a market capitalization of $235.19 million, a P/E ratio of -2.29 and a beta of 0.90. The company has a 50-day simple moving average of $3.37 and a 200 day simple moving average of $3.42. Voyager Therapeutics, Inc. has a fifty-two week low of $2.64 and a fifty-two week high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The company had revenue of $5.20 million during the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. Equities analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.